This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
TD Cowen Starts Standard BioTools With Buy Rating, $3.50 Price Target MT
Standard BioTools Inc. Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the Boundaries of Tissue Imaging CI
Jefferies Initiates Coverage on Standard BioTools With Buy Rating, $3.25 Price Target MT
Sector Update: Health Care Stocks Lean Higher Pre-Bell Thursday MT
Standard BioTools Enters Into Multi-Year Medicine Research Engagement With Bristol-Myers Squibb MT
Transcript : Standard BioTools Inc., Q4 2023 Earnings Call, Feb 28, 2024
Standard BioTools Inc. Provides Revenue Guidance for the Full Year 2024 CI
Standard BioTools Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Standard BioTools Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (LAB) STANDARD BIOTOOLS Reports Q4 Revenue $28.2M, vs. Street Est of $24.9M MT
Standard BioTools Inc. and Next Gen Diagnostics Announce Partnership to Provide Complete Automation of Low-Cost Pathogen Sequencing CI
Standard Biotools and Navignostics Announce Collaboration Agreement to Advance Imaging Capabilities in Personalized Medicine CI
Standard Biotools Inc. Provides Revenue Guidance for the Fourth Quarter and full year 2023 CI
Standard BioTools Says Merger With SomaLogic Completed MT
Standard BioTools Inc. Announces Management Changes CI
SomaLogic, Standard BioTools Receive Shareholder Approvals for Pending Merger MT
Standard BioTools Inc. completed the acquisition of SomaLogic, Inc.. CI
Standard BioTools Inc.'s Equity Buyback announced on November 28, 2022, has expired. CI
Sector Update: Health Care Stocks Advance Late Afternoon MT
SomaLogic Says Madryn Asset Management's Statement on SomaLogic-Standard BioTools Merger Misleading MT
Tranche Update on Standard BioTools Inc.'s Equity Buyback Plan announced on November 28, 2022. CI
Standard BioTools Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : Standard BioTools Inc., Q3 2023 Earnings Call, Nov 07, 2023
Earnings Flash (LAB) STANDARD BIOTOOLS Reports Q3 Revenue $25.4M, vs. Street Est of $23.6M MT
Sector Update: Health Care Stocks Mixed Premarket Wednesday MT
Chart Standard BioTools Inc.
More charts
Standard BioTools Inc. develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines. The Company's segments include Proteomics and Genomics. The Proteomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of genes and their functions. The Company provides insights in health and disease using its mass cytometry and microfluidics technologies, which serve applications in proteomics and genomic. It works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories around the world, focusing on the needs in translational and clinical research, including oncology, immunology, and immunotherapy. The Company also provides differentiated multi-omics tools for research.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.56 USD
Average target price
3.583 USD
Spread / Average Target
+39.97%
Consensus
  1. Stock Market
  2. Equities
  3. LAB Stock
  4. News Standard BioTools Inc.
  5. Insider Trends: Fluidigm Insider Converts Option/Derivative Security Sells Portion to Pay Tax, Buy Trend Intact